PI22, Jim, I've checked out BIOD-123's Phase I data and it met all it's endpoints. This drug is a second generation version of Viaject, which had good PhaseIII data but received a CRL from the FDA because of irregularities at the India site. The FDA also cited "injection site tolerability" as 2 of the reasons for the CRL. No such complaints from newer version compound [BIOD-123]. Factor in a much higher absorption rate [64%] than soc [humalog] and you should fully expect this drug to meet all endpoints and go on to a successful PhaseIII trial. didn't look at any other programs but this stock is a keeper.